List of Excipients in Branded Drug NASONEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme Corp	NASONEX	mometasone furoate monohydrate	0085-1288	BENZALKONIUM CHLORIDE
Merck Sharp & Dohme Corp	NASONEX	mometasone furoate monohydrate	0085-1288	CARBOXYMETHYLCELLULOSE SODIUM
Merck Sharp & Dohme Corp	NASONEX	mometasone furoate monohydrate	0085-1288	CELLULOSE, MICROCRYSTALLINE

Nasonex Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Nasonex is an aqueous nasal suspension containing mometasone furoate monohydrate at 50 mcg per spray. Its excipient system is built around suspension stability, dose uniformity, pump performance, preservation, and nasal tolerability. The core formulation is mature and largely commoditized, but commercial opportunities remain in preservative-free delivery, improved suspension robustness, pediatric usability, device differentiation, and regional lifecycle products.

The main commercial constraint is that mometasone nasal spray has generic competition and limited remaining composition-of-matter or formulation exclusivity. New products therefore need to win through device performance, tolerability, convenience, regulatory positioning, or differentiated distribution rather than through the active ingredient alone.

What excipients are used in Nasonex nasal spray?

Nasonex contains mometasone furoate monohydrate suspended in an aqueous vehicle. The U.S. prescribing information identifies the principal inactive ingredients as glycerin, microcrystalline cellulose and carboxymethylcellulose sodium, polysorbate 80, benzalkonium chloride, citric acid monohydrate, sodium citrate dihydrate, and purified water.[1]

Excipient	Primary function in Nasonex	Commercial and technical relevance
Microcrystalline cellulose and carboxymethylcellulose sodium	Suspending and rheology-control system	Maintains particle dispersion and supports dose uniformity
Glycerin	Humectant and tonicity modifier	Can improve perceived nasal comfort but affects viscosity and spray behavior
Polysorbate 80	Wetting and dispersion aid	Helps wet hydrophobic mometasone particles; requires control of oxidation and peroxide impurities
Benzalkonium chloride	Antimicrobial preservative	Supports multidose-container microbiological control; can create tolerability and preservative-free positioning issues
Citric acid monohydrate	Acidulant and pH adjustment	Helps maintain formulation pH
Sodium citrate dihydrate	Buffering agent	Stabilizes pH during shelf life
Purified water	Continuous phase	Controls microbial quality, osmolality, and formulation consistency

The formulation is not a simple solution. Mometasone furoate has low aqueous solubility, so the product depends on controlled particle size, wetting, suspension rheology, and container closure performance.[1]

How does the Nasonex formulation work?

Nasonex uses a structured suspension rather than a fully dissolved drug product. The cellulose-based excipient system increases viscosity and reduces particle settling. The pump must redisperse the suspension after shaking and deliver a reproducible volume with a consistent plume and droplet-size distribution.

Key critical quality attributes include:

• Mometasone particle-size distribution
• Suspension redispersibility
• Assay and delivered-dose uniformity
• Spray content uniformity
• Pump actuation force
• Droplet and particle-size distribution
• Plume geometry
• Microbial limits
• Preservative effectiveness
• pH and osmolality
• Container closure integrity

The cellulose combination is commercially important because changing the grade, substitution level, or ratio of microcrystalline cellulose to carboxymethylcellulose can alter viscosity, sedimentation, sprayability, and dose delivery. A nominally equivalent excipient substitution may therefore trigger substantial formulation and device redevelopment.

Why is benzalkonium chloride strategically important?

Benzalkonium chloride, commonly abbreviated BKC, is useful in multidose nasal products because it provides antimicrobial preservation. Its presence also creates a potential differentiation point for preservative-free products.

The commercial case for removing BKC is strongest where:

• Patients use the product chronically.
• The product targets children.
• The label seeks a “gentle” or “preservative-free” positioning.
• The product uses a sterile single-dose or preservative-free multidose device.
• Competitors already promote preservative avoidance.

The technical burden is significant. A preservative-free product requires an alternative microbiological control strategy, such as a sterile manufacturing process, a validated sterile container closure, a one-way valve, a protected nozzle, a unit-dose package, or a preservative-free multidose pump. The device becomes part of the formulation strategy.

What formulation opportunities exist for Nasonex competitors?

The strongest opportunities are incremental rather than molecule-based.

Preservative-free mometasone nasal spray

A preservative-free product can target patients concerned about nasal irritation and chronic exposure to BKC. It can also support pediatric, allergy, and long-term maintenance positioning.

Potential presentations include:

1. Unit-dose ampoules or vials.
2. Preservative-free multidose pumps.
3. Airless or mechanically protected systems.
4. Metered-dose devices with sterile fluid paths.

The main barriers are cost, sterility assurance, pump complexity, waste, and manufacturing scale. A preservative-free product must demonstrate microbiological robustness across in-use conditions, including repeated actuation, nozzle contamination, storage excursions, and consumer handling.

Lower-irritation formulations

A reformulation could adjust:

• BKC concentration or elimination
• Glycerin concentration
• Buffer strength
• pH
• Osmolality
• Surfactant level
• Cellulose grade
• Spray plume characteristics

The product cannot optimize comfort in isolation. Lower surfactant or preservative levels may reduce wetting, suspension stability, or antimicrobial performance. An apparently milder formulation may produce less consistent dosing or greater nozzle blockage.

Improved suspension systems

Alternative suspending agents may include other cellulose derivatives, xanthan gum, carbomers, or combinations of polymeric rheology modifiers. Each option changes the product’s flow behavior and may affect spray performance.

A commercially viable alternative should improve at least one measurable attribute:

• Faster redispersion after storage
• Lower shake dependence
• Reduced sediment compaction
• Better dose uniformity near the end of container life
• Lower actuation force
• Less nozzle clogging
• More consistent plume geometry

A “shake-free” or reduced-shake product would have strong usability value, but it would require convincing evidence that the suspension remains uniform throughout storage and use.

Pediatric and geriatric delivery

Pediatric products can differentiate through:

• Lower actuation force
• Smaller or softer nasal adapter
• Reduced odor or aftertaste
• Clear dose counter
• Tamper-resistant but accessible packaging
• Improved instructions for caregiver administration

Older users may value an ergonomic actuator, dose counter, and reduced priming burden. Device redesign is commercially attractive because it can support a new product profile without changing the active pharmaceutical ingredient.

What patents protect Nasonex and its formulation?

Nasonex’s principal patent estate is mature. The original nasal spray product received U.S. approval in 1997 under NDA 020762.[1] The foundational patents covering mometasone chemistry, pharmaceutical compositions, and nasal delivery were filed decades ago and have generally expired or passed the period in which they could block ordinary generic mometasone nasal spray development.

The key protection categories were:

Protection category	Relevance to Nasonex
Mometasone composition patents	Historical protection for the active corticosteroid
Pharmaceutical composition patents	Covered formulations containing mometasone furoate
Nasal delivery and use patents	Covered treatment of allergic rhinitis and related conditions
Manufacturing patents	May have covered specific synthesis, crystallization, or formulation processes
Pediatric exclusivity	Extended certain periods of regulatory protection but did not create a new long-term composition patent
OTC product protections	May involve labeling, packaging, and regulatory positioning rather than a new active-ingredient patent

The active patent risk for a new entrant is more likely to arise from a later formulation, device, manufacturing, or preservative-free system than from the original Nasonex formulation. A competitor should conduct a current freedom-to-operate search in the target jurisdiction because patent status differs by country and later device patents may not appear in the original Nasonex record.

What is the FDA Orange Book status of Nasonex?

Nasonex is associated with FDA NDA 020762. The FDA Orange Book records approved drug products, patent information, and regulatory exclusivity associated with listed products.[2]

Mometasone furoate nasal spray has generic competition in the U.S. market. FDA-approved generic products generally rely on abbreviated new drug applications and must demonstrate pharmaceutical equivalence, bioequivalence, and quality comparable to the reference product.[3]

For a nasal suspension, generic development is more complex than a conventional tablet. The applicant must address formulation sameness or permissible differences, device performance, delivered dose, spray characteristics, and local performance. FDA guidance on nasal spray and inhalation products identifies spray pattern, plume geometry, droplet-size distribution, priming, repriming, and dose uniformity as important development considerations.[4]

When did Nasonex lose exclusivity?

Nasonex lost practical U.S. market exclusivity after expiry of its original patent and regulatory protections, followed by generic approval. The product is therefore a mature branded medicine rather than a protected innovative asset.

The relevant commercial timeline is:

Event	Timing
Nasonex U.S. approval	1997
Original branded patent and exclusivity period	Largely expired
Generic mometasone nasal spray entry	Established
OTC Nasonex 24HR Allergy pathway	Approved for nonprescription use in the U.S.
Current competitive position	Brand, authorized or branded-generic products, and generics

The OTC switch created a separate commercial opportunity around consumer marketing and allergy-season demand. It did not restore prescription-style exclusivity for the active ingredient.

Which companies are challenging or competing with Nasonex?

Competition includes generic manufacturers of mometasone furoate nasal spray and branded intranasal corticosteroid products. Major therapeutic competitors include:

• Fluticasone propionate nasal spray
• Fluticasone furoate nasal spray
• Budesonide nasal spray
• Triamcinolone acetonide nasal spray
• Beclomethasone dipropionate nasal spray
• Azelastine-fluticasone combination products

The competitive decision is usually made on price, perceived tolerability, onset, OTC availability, device usability, and pharmacy substitution. Most competing products do not win through a fundamentally different excipient concept. They compete through brand awareness, retail placement, insurance status, device design, or combination therapy.

What generic entry risks exist for Nasonex?

Generic entry risk is high because the active ingredient and core therapeutic indication are established. The main residual barriers are technical and commercial.

Technical barriers

• Reproducing suspension behavior
• Matching pump dose delivery
• Controlling particle-size distribution
• Demonstrating spray-pattern equivalence
• Achieving preservative effectiveness
• Managing viscosity without impairing atomization
• Establishing in-use stability
• Maintaining performance through container depletion

Commercial barriers

• Low reimbursement for undifferentiated prescription products
• Retail price competition
• High device tooling and validation costs
• Limited brand loyalty outside the OTC channel
• Seasonal demand concentration
• Pharmacy substitution pressure

A generic can succeed with a conventional preserved formulation if it achieves reliable dose delivery and low cost. A differentiated entrant needs a clear value proposition, such as preservative-free delivery, better usability, or a lower-irritation profile.

How strong is the Nasonex patent estate?

The historical patent estate was commercially strong during the protected period but is weak as a current barrier to standard generic entry. Its residual strength lies in narrow improvements, not in broad control of mometasone nasal spray.

A practical strength assessment is:

Asset area	Current barrier strength
Mometasone active ingredient	Low
Original aqueous nasal suspension	Low to moderate, depending on claim scope and jurisdiction
Specific excipient ratios	Potentially moderate if valid claims remain
Preservative-free multidose system	Potentially moderate to high
Spray pump and actuator	Potentially moderate
Manufacturing and particle engineering	Moderate if process claims are difficult to design around
Method-of-use claims	Generally limited for routine allergic-rhinitis indications
OTC branding and packaging	Commercial protection, not strong pharmaceutical patent protection

Patent value is highest where a formulation claim is tied to measurable performance, such as improved suspension stability or spray uniformity, and where the device and formulation are difficult to separate.

What licensing and commercial opportunities exist?

The most attractive licensing targets are likely to be platform technologies rather than Nasonex-specific active-ingredient rights.

Potential deal categories include:

• Preservative-free multidose nasal pumps
• Sterile nasal suspension manufacturing
• Low-force pediatric actuators
• Spray-pattern optimization
• Excipient systems that improve redispersibility
• Particle-engineering platforms for poorly soluble corticosteroids
• Contract manufacturing of nasal suspensions
• OTC brand extensions and regional commercialization rights

A licensee should prioritize technologies that provide measurable regulatory value. A device that reduces actuation force or improves dose uniformity is easier to position than an excipient change that produces no visible patient or manufacturing benefit.

How can manufacturers build a differentiated Nasonex product?

A practical product-development strategy is:

1. Preserve the established dose and therapeutic indication.
2. Select one differentiating claim, such as preservative-free use or improved usability.
3. Develop the excipient and pump as one integrated system.
4. Test suspension stability under shipping and in-use conditions.
5. Establish comparable spray performance against the reference product.
6. Build a regulatory strategy around an abbreviated application, OTC pathway, or hybrid product route.
7. Protect the improvement with formulation, device, process, and packaging claims.
8. Launch through a channel where the differentiation matters, such as pediatric allergy care or OTC seasonal allergy.

The best commercial opportunity is unlikely to be a new excipient alone. It is a coordinated formulation-device package that reduces irritation, simplifies administration, or lowers manufacturing variability.

What revenue exposure does Nasonex create?

Nasonex has limited standalone patent-driven revenue protection because generic competition is established. Revenue depends on channel and geography:

• Prescription sales are exposed to generic substitution.
• OTC sales can support higher consumer visibility and seasonal volume.
• Markets without broad generic penetration may retain branded pricing.
• Combination products and premium devices can support higher net prices.
• Preservative-free products may command a premium if supported by clinical or usability evidence.

Organon and other brand owners do not consistently disclose Nasonex revenue as a separate global line item in public financial reporting. Product-specific revenue estimates should therefore not be inferred from corporate respiratory or consumer-health totals.[5]

Key Takeaways

• Nasonex uses a mature aqueous suspension containing cellulose-based suspending agents, glycerin, polysorbate 80, benzalkonium chloride, citrate buffer, and water.
• The core commercial challenge is dose uniformity, not simple solubility.
• BKC removal is the clearest excipient-led differentiation opportunity.
• Preservative-free products require device, sterility, packaging, and microbiological redesign.
• The original Nasonex patent estate is largely expired as a barrier to standard generic entry.
• New protection is more likely around excipient combinations, spray devices, manufacturing processes, and preservative-free systems.
• Generic competition makes an undifferentiated mometasone nasal spray commercially weak.
• The strongest licensing opportunities involve nasal delivery platforms and sterile multidose technologies.
• OTC positioning, pediatric usability, and reduced-irritation claims offer the clearest routes to premium economics.

FAQs

Can benzalkonium chloride be removed from a Nasonex generic?

Yes, but removal changes the regulatory and technical profile. The applicant would need a validated alternative microbiological control strategy and evidence that the product remains safe and stable during repeated use.

Is a preservative-free mometasone nasal spray automatically substitutable with Nasonex?

No. Substitution depends on regulatory approval, product labeling, device characteristics, pharmacy rules, and the applicable jurisdiction. Preservative-free status alone does not establish pharmaceutical equivalence.

Which excipient is most important for Nasonex suspension stability?

The microcrystalline cellulose and carboxymethylcellulose sodium system is central because it controls rheology, particle settling, redispersion, and dose uniformity.

Can a manufacturer patent a new Nasonex excipient combination?

Yes, if the formulation is novel and non-obvious and produces credible technical benefits. Broad claims covering ordinary excipient substitutions are difficult to defend when the ingredients and functions are already known.

Does Nasonex have biosimilar risk?

No. Nasonex contains a chemically synthesized small-molecule corticosteroid, not a biologic. Its principal competitive risk comes from generic drug products and alternative intranasal corticosteroids, not biosimilars.

References

1. U.S. Food and Drug Administration. (2024). Nasonex 24HR Allergy and Nasonex nasal spray prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Generic drug development requirements.
4. U.S. Food and Drug Administration. (2002). Nasal spray and inhalation solution, suspension, and spray drug products: Chemistry, manufacturing, and controls documentation.
5. Organon & Co. (2024). Annual report and Form 10-K.